A marker gene for predicting recurrence of stage II colorectal cancer and its application

Abstract

The present invention discloses a marker gene and its application for predicting the recurrence of stage II colorectal cancer. The present invention uses gene chip meta-analysis technology to identify public differentially expressed genes related to the recurrence of stage II colorectal cancer patients. The model predicts stage II colorectal cancer. The AUC value of the 5-year recurrence risk of colorectal cancer patients is 0.806, which can significantly separate patients with high recurrence risk and low recurrence risk in the test set; the present invention uses the Lasso Cox regression model, which not only plays the role of model establishment but also The role of variable importance screening can greatly reduce the variable dimension of the model, which will help reduce the cost of gene expression detection and facilitate the promotion of the model in clinical applications.

Description

(1) Technical field [0001] The present invention relates to the field of bioinformatics, in particular to the identification of public differentially expressed genes related to the recurrence of stage II colorectal cancer using gene chip meta-analysis technology, and the construction of a stage II colorectal cancer based on public differentially expressed genes and the Lasso Cox model Patient tumor recurrence prediction model. (2) Background technology [0002] Colorectal cancer is one of the most common malignant tumors in the world, ranking third in incidence and fourth in mortality among various malignant tumors. In recent years, with the improvement of the people's economic level and the change of lifestyle, the incidence of colorectal cancer in my country is gradually increasing and showing a younger trend. The number of new colorectal cancer patients increases by about 4% every year. [0003] The treatment of colorectal cancer is mainly surgical treatment, supplemente...

AI Technical Summary

Problems solved by technology

However, many current clinical studies have found that the definition of high-risk stage II is not accurate. Many high-risk stage II patients have no recurrence, while some general-risk stage II patients have recurrence and metastasis. This may be related to the traditional high-risk factors. The clinicopathological characteristics of the patient are not considered, and the biological characteristics of the tumor itself are not considered. However, the current gene chip technology and high-throughput sequencing technology can allow researchers to better mine the gene expression information of the tumor, and then reflect the biology of the tumor. feature

Images